Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Accumulated Expenses (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Accumulated Expenses for 15 consecutive years, with $78000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses fell 78.8% year-over-year to $78000.0, compared with a TTM value of $78000.0 through Sep 2025, down 78.8%, and an annual FY2024 reading of $176000.0, down 69.01% over the prior year.
  • Accumulated Expenses was $78000.0 for Q3 2025 at Alaunos Therapeutics, down from $265000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $14.0 million in Q3 2021 and bottomed at $78000.0 in Q3 2025.
  • Average Accumulated Expenses over 5 years is $3.7 million, with a median of $3.1 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses plummeted 96.09% in 2021, then skyrocketed 881.83% in 2022.
  • Year by year, Accumulated Expenses stood at $6.1 million in 2021, then dropped by 10.24% to $5.5 million in 2022, then tumbled by 89.59% to $568000.0 in 2023, then plummeted by 69.01% to $176000.0 in 2024, then plummeted by 55.68% to $78000.0 in 2025.
  • Business Quant data shows Accumulated Expenses for TCRT at $78000.0 in Q3 2025, $265000.0 in Q2 2025, and $231000.0 in Q1 2025.